Summary of the Conference Call for Staily Company Company Overview - Staily is a leading supplier of iodine contrast agents in China, with the largest product scale and variety in the market. The production capacity and output of Iohexol rank among the top in the country. [2][3] Industry Insights - The iodine contrast agent market in China is expected to recover to a scale of 15 billion RMB by 2024, following the impact of centralized procurement in 2021. [6] - The global X-ray contrast agent market accounts for 72.5% of the total contrast agent market, with Iohexol, Iopamidol, and Ioversol holding market shares of 31.5%, 18%, and 14.1% respectively. [5] Key Financial Metrics - The compound annual growth rate (CAGR) of domestic formulation revenue over the past five years reached 161%, increasing from 12 million RMB in 2020 to 558 million RMB in 2024. [4] - Projected revenues for 2025, 2026, and 2027 are 2.504 billion RMB, 2.818 billion RMB, and 3.221 billion RMB respectively, with net profits of 46 million RMB, 169 million RMB, and 322 million RMB. [4][15] Production Capacity and Cost Management - Staily has established over 2,400 tons of raw material capacity, with 1,800 tons certified for domestic and international quality systems. This is expected to increase to 3,000 tons by the end of the year, covering nearly one-third of global demand. [2][8] - Gross margin improvements are attributed to declining iodine prices, increased capacity utilization, and cost reduction through point recovery technology, which has reached original research levels. [11] Internationalization Strategy - Staily is actively promoting the international sales of formulations through the registered advantages and sales network of its Irish subsidiary, IMAX. As of 2024, IMAX's overseas formulation sales reached 86.2 million RMB. [2][3] Future Growth Drivers - The company anticipates a doubling of internal shipment volume from 400 tons to 800 tons over the next 3 to 4 years due to the new production capacity from the intelligent transformation project in Shanghai. [10] - The company is expected to benefit from the completion of European GMP certification for its Shanghai factory, which will enhance production efficiency and reduce costs for overseas markets. [13] Valuation and Investment Potential - As of the last trading day, Staily's closing price was 9.46 RMB, with a total market capitalization of approximately 4.1 billion RMB. The company is projected to have a price-to-earnings ratio of 95x, 24x, and 13x for the years 2025, 2026, and 2027 respectively, indicating a favorable investment value. [15]

Core Viewpoint - Pacific Securities report indicates that Sitaili is a leading enterprise in the iodine contrast agent "API + formulation" integration, with a steadily advancing internationalization strategy. The competitive landscape of the contrast agent industry is relatively concentrated, and the market size is expected to double in the future. [1] Group 1: Company Overview - Sitaili is positioned as a leader in the iodine contrast agent sector, focusing on both active pharmaceutical ingredients (API) and formulations [1] - The company is nearing the completion of large-scale production capacity investments, which will support the anticipated increase in demand for raw materials [1] Group 2: Market Potential - The contrast agent industry is expected to see a doubling in market size due to its concentrated competitive landscape [1] - Domestic formulation products are expected to gradually increase in volume through centralized procurement [1] Group 3: Growth and Profitability - The overseas formulation business is entering a phase of rapid growth as production processes are streamlined [1] - Profitability is anticipated to improve gradually, with the potential for accelerated profit growth [1] - The company's valuation is expected to command a premium, leading to a "buy" rating for the stock [1]

Summary of the Conference Call for Sitaly Company Overview - Sitaly has been established since 1997 and is a leading player in the iodine contrast agent market, holding the largest production capacity and the most comprehensive product range in China. The company has a significant global presence and influence in the industry [3][4]. Industry Insights - The iodine contrast agent market is characterized by substantial growth potential and high entry barriers, with few global participants. Demand is expected to grow from 10,000 tons to 20,000 tons over the next decade, particularly in emerging markets like China [2][4]. - The industry is projected to maintain a stable competitive landscape due to cautious expansion plans from other companies [5]. Financial Performance - Sitaly is expected to achieve a compound annual growth rate (CAGR) of nearly 18% in revenue from 2018 to 2024, indicating stable growth despite initial profit fluctuations due to capacity investments [2][3]. - Projected net profits for the next three years are estimated at 96 million yuan, 245 million yuan, and 360 million yuan respectively. The current stock price corresponds to a price-to-earnings (P/E) ratio of approximately 14 times for 2026, suggesting attractive valuation [4][10]. Competitive Advantages - Sitaly has made significant technological investments and has obtained regulatory certifications in major markets including China, the US, Europe, and Japan, enhancing its competitive edge in new product registrations [2][6]. - The raw material drug business is supported by three major production bases, with expected revenue from iodine contrast agent raw materials and intermediates reaching approximately 1.2 billion yuan in 2024, accounting for over half of total revenue. The company is well-prepared to capture the transfer of production capacity from Europe and the US [7][9]. Business Segments - The formulation business is primarily focused on the domestic market, with projected revenue of 558 million yuan in 2024, reflecting a year-on-year growth of 14%. The overseas formulation platform is expected to grow rapidly by 60%, reaching around 86 million yuan [8][9]. - The company has secured bids for three core iodine contrast agent products, laying the groundwork for future sales and addressing long-standing supply-demand issues [9]. Long-term Outlook - Sitaly's global strategy implementation is anticipated to drive economies of scale and optimize product structure, leading to sustained performance growth. The company is expected to benefit from its existing fixed assets and ongoing projects, which could support revenue levels exceeding 6 billion yuan with a net profit margin of around 10% [10].